A retrospective review of heart transplant recipients has indicated the possible involvement of Lp(a) in the development of cardiac allograft vasculopathy (CAV) – a major cause of morbidity and mortality after heart transplantation.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.